The purchase will be made from December 8, 2014 to May 19, 2015, which is the day before the Annual General Meeting 2015. The purchase of shares shall take place on NASDAQ OMX Stockholm and may only occur at a price within the share price interval registered at that time. The share price interval is the price interval between the highest buying price and the lowest selling price. The purpose of the purchase is to cover social security fees under the PSP 2014 II incentive that was resolved at the Extraordinary General Meeting on December 4, 2014. Prior to the above decision, Karolinska Development holds 236,607 own shares.
For further information, please contact:
Bruno Lucidi, CEO, Karolinska Development AB
Phone: +46 (0) 72 245 9892, e-mail: Bruno.lucidi@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX (KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.
